EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B

Steven W Pipe, Wolfgang Miesbach iD, Michael Recht, Frank W G Leebeek, Nigel S Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens iD, Sandra Le Quellec, Vaibhav Mahajan, Sean Gill, Douglass Drelich und 2 weitere

New England Journal of Medicine · 29.01.2026 · 394 (5) · 463-474

DOI: 10.1056/nejmoa2514332 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 29.01.2026. Verfasst von Steven W Pipe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Factor IX, Genetic Therapy, Hemophilia B, Hemorrhage. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: CSL Behring, uniQure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXGenetic TherapyHemophilia BHemorrhageGene Therapy AgentsAdultHumansMaleMiddle AgedDependovirusFollow-Up StudiesGenetic VectorsInfusions, Intravenous

Substanzen

Factor IXetranacogene dezaparvovecfactor IX-Padua

Autor:innen und Institutionen

  • Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor.
  • University Hospital Frankfurt, Frankfurt, Germany.
  • Yale School of Medicine, New Haven, CT.
  • National Bleeding Disorders Foundation, New York.
  • Department of Hematology, Erasmus University Medical Center (UMC) Rotterdam, Rotterdam, the Netherlands.
  • Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill.

ORCID-Profile: Wolfgang Miesbach, Michiel Coppens

Förderung

  • CSL Behring
  • uniQure

Zitieren

APA

Pipe, S. W., Miesbach, W., Recht, M., Leebeek, F. W. G., Key, N. S., Castaman, G., Lattimore, S., Coppens, M., Le Quellec, S., Mahajan, V., Gill, S., Drelich, D., Monahan, P. E., & HOPE-B Study Group Investigators (2026). Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine, 394(5), 463-474. https://doi.org/10.1056/nejmoa2514332

Vancouver

Pipe SW, Miesbach W, Recht M, Leebeek FWG, Key NS, Castaman G, et al. Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine. 2026;394(5):463-474. doi:10.1056/nejmoa2514332

BibTeX
@article{Pipe2026,
  author = {Pipe, Steven W and Miesbach, Wolfgang and Recht, Michael and Leebeek, Frank W G and Key, Nigel S and Castaman, Giancarlo and Lattimore, Susan and Coppens, Michiel and Le Quellec, Sandra and Mahajan, Vaibhav and Gill, Sean and Drelich, Douglass and Monahan, Paul E and HOPE-B Study Group Investigators, HOPE-B Study Group Investigators},
  title = {Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {5},
  pages = {463--474},
  doi = {10.1056/nejmoa2514332}
}
Kostenlos starten →